丝裂原活化蛋白激酶抑制剂对儿童的皮肤不良反应
Adverse cutaneous effects of mitogen-activated protein kinase inhibitors in children.
作者信息
Dávila Osorio Victoria Lucia, Vicente María Asunción, Baselga Eulalia, Salvador Hector, Cruz Ofelia, Prat Carolina
机构信息
Department of Dermatology Hospital Sant Joan de Deu, Barcelona, Spain.
Department of Oncology Hospital Sant Joan de Deu, Barcelona, Spain.
出版信息
Pediatr Dermatol. 2021 Mar;38(2):420-423. doi: 10.1111/pde.14354. Epub 2020 Dec 27.
BACKGROUND
Mitogen-activated protein kinase inhibitors (MEKi) are currently used for the treatment of central nervous system tumors in children and have shown promising results. Cutaneous adverse effects are among the most common toxicities described in adults, but few studies exist in pediatric patients.
OBJECTIVE
We aimed to describe the cutaneous adverse effects associated with MEKi in pediatric patients.
METHODS
A retrospective study was carried out at our pediatric hospital in Barcelona, Spain, in patients undergoing treatment with MEKi.
RESULTS
Sixty-one children between 1 and 18 years of age were included. All patients developed cutaneous toxicity. Eczema, hair abnormalities, oral aphthae, and paronychia were among the most common cutaneous side effects.
CONCLUSIONS
Recognizing skin toxicity in pediatric patients under treatment with MEKi is essential to establishing appropriate education and therapy, thereby improving treatment tolerability and minimizing avoidable interruptions in treatment.
背景
丝裂原活化蛋白激酶抑制剂（MEKi）目前用于治疗儿童中枢神经系统肿瘤，并已显示出有前景的结果。皮肤不良反应是成人中描述的最常见毒性之一，但儿科患者的相关研究较少。
目的
我们旨在描述儿科患者中与MEKi相关的皮肤不良反应。
方法
在西班牙巴塞罗那的我们的儿科医院对接受MEKi治疗的患者进行了一项回顾性研究。
结果
纳入了61名1至18岁的儿童。所有患者均出现皮肤毒性。湿疹、毛发异常、口腔溃疡和甲沟炎是最常见的皮肤副作用。
结论
认识到接受MEKi治疗的儿科患者的皮肤毒性对于开展适当的教育和治疗至关重要，从而提高治疗耐受性并尽量减少可避免的治疗中断。
Zotero 插件